China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) experienced a steep share price decline Thursday, dropping 77% following the company's disclosure of a registered direct offering intended to raise roughly $9 million. Management said the planned sale will create material dilution for existing shareholders.
Under the terms of a securities purchase agreement with institutional investors, China SXT agreed to sell 4,500,000 units at a price of $2.00 per unit. Each unit is composed of one Class A ordinary share and one warrant carrying an exercise price of $3.20 per share.
The company stated that the warrants will be immediately exercisable upon issuance and will expire one year from their issuance date. China SXT expects to receive approximately $9 million in gross proceeds from the transaction, before placement agent fees and other offering-related expenses are deducted.
Closing of the transaction is anticipated to occur on or about July 24, 2025, but remains subject to customary closing conditions. Univest Securities, LLC has been appointed as the sole placement agent for the offering.
Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China SXT Pharmaceuticals focuses on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces. The company is listed on the Nasdaq under the ticker SXTC.
Details of the offering:
- Number of units to be sold: 4,500,000
- Price per unit: $2.00
- Unit composition: one Class A ordinary share plus one warrant
- Warrant exercise price: $3.20
- Warrant exercisability and term: immediately exercisable; expires one year after issuance
- Estimated gross proceeds: approximately $9 million (before fees and offering expenses)
- Expected close date: on or about July 24, 2025, subject to customary closing conditions
- Sole placement agent: Univest Securities, LLC
The market reaction to the funding announcement was severe, reflecting investor concern about the scale of dilution implied by the unit structure and the issuance of near-term exercisable warrants. The company did not provide additional operational or strategic detail beyond the financing terms and the expected timing of the closing.
Context and implications:
The financing is structured to deliver immediate capital but also grants investors the right to acquire additional shares through warrants exercisable at $3.20 within one year. The gross proceeds figure does not account for placement agent fees and other expenses associated with closing the offering.
As of the announcement, investors and market participants will be watching for final closing and any further statements from the company regarding use of proceeds or changes to corporate strategy.